METHODS This MFM* is a 3 Dimensional braided tube made of several interconnected layers without any covering. Our earliest in vitro (theorical simulation), computerized Fluid dynamics, Molecular Modelization and in vivo tests demonstrated that this MFM* reduces the velocity in the aneurismal sac up to 90% by modifying the hemodynamic conditions. A saccular aneurysm without collateral branch will thrombose quickly. If a collateral branch is present the flow is directed towards this branch leading to shrinkage of the aneurysm. Animal experiments show excellent results. Moreover, as demonstrated in animal and human studies this MFM* preserves the collateral branches allowing the possibility to cover any artery without compromising the flow (renal, digestive arteries, supra aortic vessels.)
RESULTS 44 peripheral An. (iliac:23, femoral:1, popliteal:5, renal:8, mesenteric:2, carotid: 2, Subclavian : 2, Caeliac trunk :1) were treated with the MFM* (male:31, mean age 62þ/-8 y) (57 stents ⌀ 5 to 14 mm; length 40 to 120 mm) were implanted to treat these aneurysms, by femoral approach (43 cases), brachial approach (1 case), Technical success in all patients. No complications. All An. thrombosed with diameter reduction in some pts. The thrombosis could take several weeks depending on the importance of collateral branches. 6 month to 36 month follow up will be presented and we will discuss the time needed to achieve exclusion of the An. All the side branches remained patent. METHODS This MFM* is a 3D braided tube made of several interconnected layers without any covering. Our earliest tests, in vitro (theorical simulation computerized Fluid dynamics, Molecular Modelization) & in vivo. demonstrate that this MFM* reduces the velocity in the aneurismal sac up to 90% by modifying the hemodynamic conditions.. A saccular aneurysm (A.) without collateral branch will thrombose quickly. If a collateral branch is present the flow is directed towards this branch leading to shrinkage of the aneurysm. In fusiform A. the flow is laminated, the vortexes eliminated, eliminating the risk of rupture. Animal experiments show excellent results. Moreover, as demonstrated in animal and human studies this MFM preserves the collateral branches and increases the flow in them, allowing the possibility to cover any artery without compromising the flow.
CONCLUSIONS
RESULTS 9 RAAs (right: 6, left: 3) in 9 pts (male: 4) mean age 58 y. treated with MFM* 7 pts had atheromatous disease, 2 a fibromuscular dysplasia. One pt had a solitary kidney. All these pts had hypertension. 11 MFM*(⌀: 5 to 7 mm, length 30 to 60 mm) loaded in a 6 F sheath implanted by femoral approach through 8 F guiding catheter. These stents covered major renal branches without compromising the flow. Technical success: 100%. No complications. Immediately: important reduction of the velocities inside the aneurismal sac. 6 to 36 month follow up will be presented. All aneurysms thrombosed with diameter reduction in some pts. The thrombosis could take several weeks depending on the importance of collateral branches. All the side branches remain patent.
CONCLUSIONS The MFM* is a new technique which seems promising to treat RAAs. Collateral branches can be covered without compromising the flow and risk of renal infarction. It is a safe procedure with a very low complications rate. Larger study is ongoing. 
